New pharma boss: Next EU Commission should be clear on how to protect innovation
The next EU Commission should take a stronger position on innovation in the pharma sector, the new leader of the European Federation of Pharmaceutical Industries and Associations (EFPIA) told...
View ArticleCzech drug policy shifts toward patients with rare diseases
The Czech government has launched a legislative initiative to improve access to most modern medications and rare disease drugs, Health Minister Adam Vojtěch told EURACTIV in an interview, adding that...
View ArticleWhat European patients need: a shot of some good old Belgian surrealism
In art, Belgium is internationally recognised as the land of surrealism, where reality and dreams are intertwined to offer a new perspective on the world. Life sciences is another Belgian specialty and...
View ArticleBetter access to health innovation is Kyriakides’ top priority (and hardest...
With increased powers, Health Commissioner-designate Stella Kyriakides is tasked with striking a difficult balance between making sure there is a steady supply of affordable medicines and ensuring that...
View ArticleMeasles hit Zagreb as social media join fight against anti-vaccination
Seven people have been diagnosed with measles in Zagreb in the past two weeks, raising concerns that more cases of this highly contagious virus may occur in light of the rising anti-vaccination campaigns.
View ArticleHealthy vaccines ecosystem: A tough equation to solve
In a fragmented EU market, the vaccines ecosystem is complex and in order for it to be “healthy” all relevant stakeholders should be taken into account, Professor Panos Kanavos, an associate professor...
View ArticleEU cancer plan will succeed if the right priorities are identified, official...
The much-awaited EU cancer plan will first have to identify specific needs at national level, seek funding and then be closely monitored in order to be successful, a high-ranking EU official has told...
View ArticleNew EU Commission should take on rheumatic and musculoskeletal diseases
The new European Commission should tackle "head-on" rheumatic and musculoskeletal diseases, the president of the European League Against Rheumatism (Eular) told EURACTIV in an interview, referring to...
View ArticleEU health sector ‘up to a decade’ behind others for digitalisation,...
The EU health sector is in the middle of a defining moment but the sector is “up to a decade” behind other sectors in terms of digitalisation, Deputy Director-General for Health and Food Safety Martin...
View Article‘This is personal’: Von der Leyen launches consultation on EU’s Cancer Plan
The President of the European Commission launched an EU-wide public consultation on Europe's Beating Cancer Plan on Tuesday (4 February), announcing an EU-wide "open health data space" in support of...
View ArticleCommission’s new Pharmaceutical Strategy wants to touch core issues
The European Commission is planning to re-open basically all files related to the pharmaceutical industry with its roadmap for a new Pharmaceutical Strategy, seen by EURACTIV.com.
View ArticlePharma boss: EU will have to focus on long-term medical research ecosystem
After the coronavirus crisis is over, Europe will need policies that can create a research ecosystem in the long run as well as ensure access to medicines to the patients who need them in a way that is...
View ArticleCommission aims to bring back medicine production to Europe
The EU needs to focus on ways to bring the production of medicines and pharmaceutical ingredients back to Europe to avoid a future recurrence of shortages experienced during the COVID-19 crisis, the EU...
View ArticleNew health tools for COVID-19
How to ensure access for all to a coronavirus vaccine should be the priority for world leaders. Dr Bernard Pécoul offers five ideas leaders should consider this week as they aim to raise €7.5 billion...
View ArticleOxfam: COVID-19 vaccinations for vulnerable could cost fraction of top...
Oxfam is urging governments and pharmaceutical companies to guarantee that vaccines, tests, and treatments will be patent-free and equitably distributed to all nations and people, ahead of the World...
View ArticleFranco-German couple sets eyes on EU health sovereignty
A joint COVID-19 recovery proposal put forward by French President Emmanuel Macron and German Chancellor Angela Merkel on Monday (18 May) calls for a new European approach to health crises, aiming for...
View ArticleNGOs call for moratorium on controversial ‘gene drive organisms’
After over 78 environmental and agricultural organisations signing a letter this week calling for a moratorium on gene drive technology, EURACTIV took a closer look at the controversial technology to...
View ArticleCommission’s ‘risky’ move to re-visit orphan drugs regulation
The European Commission is expected to present by the end of July an evaluation study on the pros and cons of the application of orphan and paediatric regulations, which deal with a niche segment of...
View ArticleReviewing orphan drugs law: A tough equation
The Orphan Regulation was introduced in 2000 and its main objective was to address the challenge of regulating medicines which treat patients with rare diseases. Around 246,000 people suffer from such...
View ArticleMEP: A common EU tool to incentivise production and availability of orphan drugs
When it comes to rare diseases and 'orphan drugs', technology is there to support an “objective” EU tool that could provide the pharma industry with the necessary incentives to research and produce...
View ArticleTaking action on the global threat of superbugs
COVID-19 has demonstrated in a quite dramatic way the huge impact of a global threat on public health and economy. While the COVID-19 crisis took us by surprise, our world faces a silent threat that is...
View ArticleEarly stakeholder dialogues crucial for success of rare orphan medicines
Early dialogue between stakeholders is crucial for the effective development and success of rare orphan drugs, used to treat patients with rare diseases, Anna Bucsics, project adviser at the mechanism...
View ArticleCOVID-19: Time to show citizens that they can count on Europe
European citizens have been exemplary in their fight against COVID 19. They have bravely overcome an acute sanitary threat and paid the high economic, social and psychological price of the lockdown,...
View ArticlePoor investment in digitising health hit Europe back with COVID-19
The COVID-19 pandemic has reminded Europe that its piecemeal approach to investing in the digitisation of health systems comes at a cost, but not all countries and policymakers have yet learned the...
View ArticleCommission urged to consider common regulatory framework for nanomedicines
The lack of a fit-for-purpose regulatory framework on nanomedicines and their “generics” poses risks for the safety of EU patients and this is something that the European Commission should urgently...
View ArticleReport: Without orphan drugs law, 2mn patients deprived access to therapies
In the absence of the EU orphan drugs regulation, which focuses on rare diseases, approximately two million patients would not get access to therapies, a new industry-funded report has found.
View ArticleInnovation and patients at the core of EU orphan drugs law review
The EU's Orphan Regulation was introduced in 2000 and its main objective was to address the challenge of regulating medicines which treat an estimated 30 million patients with rare diseases across the EU.
View ArticleEconomist: ‘Premature’ to decide changes in Orphan Drugs law
Europe needs to give EU Orphan Drugs regulation more time to show its effectiveness before reviewing the incentives it provides and putting pharma innovation to the test, economist Adam Hutchings told...
View ArticleCOVID-19 further complicated ‘biggest cancer killer’ diagnosis
There is an urgent need for specific recommendations over lung-cancer screening at the highest political levels in order to detect early and tackle lung cancer, the “biggest killer cancer”,...
View ArticleEU leaked pharma strategy pushes innovation for a resilient Europe
Affordability, availability and sustainability are the main focus points of the EU’s new pharmaceutical strategy, due to be published on Wednesday (25 November).
View ArticleEU ponders new incentives for novel antibiotics
The European Commission will examine specific incentives and a new pricing system to develop innovative antibiotics in its pharmaceutical strategy, in a bid to take a more ambitious stance against the...
View ArticleMEP: Parliament will pressure Commission to focus on nanomedicines
The European Parliament will put pressure on the Commission and the member states to provide the necessary regulatory framework for nanomedicines in order to better make use of their potential for...
View ArticleAntimicrobial resistance – a silent pandemic requiring global action now
If policymakers fail to address the challenge of antimicrobial resistance they risk seeing the rise of a silent pandemic, write Stella Kyriakides and Dr Tedros Adhanom Ghebreyesus.
View ArticleTime to put healthcare at the heart of the digital age
European healthcare stands at a crossroads. It is time to fully embrace AI and digital technology, argues Jan-Philipp Beck.
View ArticleEU action to turn the AMR tide looks at different incentive models
EU policymakers are being urged to consider the full range of new incentive systems and pilot innovative approaches to tackle antimicrobial resistance (AMR), including Netflix-style subscription...
View ArticlePharma rules overhaul steals scene of EU’s 2022 health agenda
The revision of the legislative framework of pharmaceuticals and of medicines for children and rare diseases will drop the curtain on next year's Commission agenda as they are expected to be adopted in...
View ArticleMEPs call for the EU pharma strategy to address medicine shortages
MEPs adopted a draft report on Tuesday (12 October) aimed at strengthening the EU's pharmaceutical strategy to ensure every patient has reliable and timely access to medicines, as shortages have been...
View Article€2.4 bn ‘Innovative Health Initiative’ to better address current health issues
The public-private partnership ‘Innovative Health Initiative’ (IHI), built on the 14 years of experience from the previous ‘Innovative Medicines Initiative’(IMI), expands its scope, focusing less...
View ArticleCommission: Pharma companies need incentives to develop orphan drugs
The market will not regulate itself when it comes to finding solutions to rare diseases, said Sandra Gallina, director at the European Commission’s DG SANTE, adding there is pressure to kickstart...
View ArticleRevision of orphan and paediatric drug framework needed, say reports
Both the European Parliament and the World Health Organisation (WHO) have reiterated the need to update the regulations on medicines for children and orphan drugs, in order to better address unmet...
View ArticlePharma CEO: Gap between EU vision and national competencies affects health...
Despite an exceptional unity of intent during the pandemic, the revision of the bloc's pharmaceutical legislation could suffer a bump between the EU's vision for health and this is still conceived at...
View Article--- Article Not Found! ---
*** *** *** RSSing Note: Article is missing! We don't know where we put it!!. *** ***
View Article--- Article Not Found! ---
*** *** *** RSSing Note: Article is missing! We don't know where we put it!!. *** ***
View Article--- Article Not Found! ---
*** *** *** RSSing Note: Article is missing! We don't know where we put it!!. *** ***
View Article--- Article Not Found! ---
*** *** *** RSSing Note: Article is missing! We don't know where we put it!!. *** ***
View ArticleHow the AI Act could unintentionally impact access to healthcare [Promoted...
MedTech Europe welcomes the efforts made by the European institutions towards giving citizens the confidence to embrace AI solutions. As the negotiations continue, further consideration is needed to...
View ArticleCommission to seek patient-centred, industry-friendly pharma rules reform
With only a few weeks before unveiling the EU's revamped framework for pharmaceuticals, Health Commissioner Stella Kyriakides described the main drivers of the much-awaited reform, stressing the...
View ArticleEU pharma reform delayed again due to Commission’s busy agenda
The unveiling of the much-awaited reform of the EU's regulatory framework for pharmaceuticals has been pushed back to a later date for the third time in just a few months, EURACTIV has learnt.
View ArticleDelay of EU pharma reform faces criticism from MEPs, stakeholders
The further postponement of the publication of the EU pharma legislation has caused tensions to rise among EU lawmakers and health stakeholders, who have demanded the Commission expedite it to start...
View ArticleLEAK: Commission enlists help of stakeholders to reshape EU pharma sector
The European Commission will call for "cooperation between different stakeholders to bring about positive change" in the pharmaceutical sector, according to a leaked communication accompanying the...
View Article
